Pharma Commercial Mock
← All views
Competitive intelligence

CI feed

Conference abstracts + payer decisions interleaved chronologically — the CI team aims to publish a structured briefing within 48 hours of any high-relevance event landing here.

45 items in window · 0 high-relevance

type:allabstractspayer decisionsrelevance:allhighmediumlow
  1. Payerlow (36%)state medicaid pdladded
    2025-06-06
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:PAlives: 14,726,433effective: 2025-07-22
    Decision affects adjacent indication; potential read-through to ZENVARA.
  2. Payerlow (23%)state medicaid pdlremoved
    2025-06-09
    California DHCS removed ZENVARA from formulary effective 2025-06-10.
    California DHCSUS-state:GAlives: 14,597,840effective: 2025-06-10
    Decision concerns ZENVARA's reference product.
  3. Payerlow (38%)pbm medicare pdpadded
    2025-06-13
    Express Scripts Medicare added ZENVARA to NSCLC formulary tier 3 with PA.
    Express Scripts MedicareUS-nationallives: 8,272,569effective: 2025-06-30
    Decision affects adjacent indication; potential read-through to ZENVARA.
  4. Payerlow (39%)pbm medicare pdprestriction added
    2025-06-15
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 5,391,705effective: 2025-07-28
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: QL
  5. Payerlow (20%)dod tricareremoved
    2025-06-17
    DoD TRICARE removed ZENVARA from formulary effective 2025-07-25.
    DoD TRICAREUS-nationallives: 9,075,802effective: 2025-07-25
    Decision affects adjacent indication; potential read-through to ZENVARA.
  6. Payerlow (29%)hta intlvalue assessment final
    2025-06-19
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)EU-DElives: 39,012,354effective: 2025-06-19
    Class-wide implications relevant to all assets with this mechanism.
  7. Payerlow (20%)hospital pt committeeadded
    2025-06-20
    HCA Healthcare added ZENVARA to NSCLC formulary tier 3 with PA.
    HCA HealthcareUS-nationallives: 457,769effective: 2025-08-12
    Class-wide implications relevant to all assets with this mechanism.
  8. Payerlow (21%)pbm medicare pdptier changed
    2025-06-21
    Humana Pharmacy Solutions moved ZENVARA from preferred to non-preferred tier.
    Humana Pharmacy SolutionsUS-nationallives: 7,345,172effective: 2025-07-16
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 4
  9. Payerlow (20%)pbm commercialadded
    2025-06-30
    Express Scripts added ZENVARA to NSCLC formulary tier 3 with PA.
    Express ScriptsUS-nationallives: 85,843,785effective: 2025-08-29
    Class-wide implications relevant to all assets with this mechanism.
  10. Payerlow (21%)cms lcdcoverage decision
    2025-07-01
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J15lives: 8,924,098effective: 2025-07-01
    Decision concerns ZENVARA's reference product.
  11. Payerlow (20%)pbm commercialstep therapy imposed
    2025-07-02
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 86,120,052effective: 2025-08-18
    Decision concerns ZENVARA's reference product.
    restrictions: QL,PA
  12. Payerlow (29%)state medicaid pdlremoved
    2025-07-02
    Texas HHSC removed ZENVARA from formulary effective 2025-08-24.
    Texas HHSCUS-state:MIlives: 6,741,526effective: 2025-08-24
    Class-wide implications relevant to all assets with this mechanism.
  13. Payerlow (34%)cms lcdcoverage decision
    2025-07-06
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 3,910,041effective: 2025-07-06
    Class-wide implications relevant to all assets with this mechanism.
  14. Payerlow (34%)state medicaid pdlpdl preferred status changed
    2025-07-11
    Florida AHCA updated PDL preferred status for ZENVARA.
    Florida AHCAUS-state:NYlives: 11,504,070effective: 2025-07-11
    Class-wide implications relevant to all assets with this mechanism.
  15. Payerlow (29%)pbm medicare pdpremoved
    2025-07-15
    CVS Caremark SilverScript removed ZENVARA from formulary effective 2025-07-15.
    CVS Caremark SilverScriptUS-nationallives: 8,152,209effective: 2025-07-15
    Decision affects adjacent indication; potential read-through to ZENVARA.
  16. Payerlow (32%)state medicaid pdlpdl preferred status changed
    2025-07-17
    California DHCS updated PDL preferred status for ZENVARA.
    California DHCSUS-state:CAlives: 12,118,580effective: 2025-07-17
    Decision affects adjacent indication; potential read-through to ZENVARA.
  17. Payerlow (35%)health plan commercialtier changed
    2025-07-17
    Aetna moved ZENVARA from preferred to non-preferred tier.
    AetnaUS-nationallives: 14,166,090effective: 2025-09-12
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 3tier_after: 3
  18. Payerlow (32%)pbm commercialexcluded
    2025-07-18
    Express Scripts excluded ZENVARA from 2026 formulary effective 2025-08-02.
    Express ScriptsUS-nationallives: 78,161,365effective: 2025-08-02
    Decision affects adjacent indication; potential read-through to ZENVARA.
  19. Payerlow (26%)pbm commercialrestriction added
    2025-07-18
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 88,088,431effective: 2025-08-22
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: ST
  20. Payerlow (29%)cms lcdcoverage decision
    2025-07-21
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 11,993,039effective: 2025-07-21
    Decision affects adjacent indication; potential read-through to ZENVARA.
  21. Payerlow (26%)cms lcdcoverage decision
    2025-07-21
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JNlives: 8,175,588effective: 2025-07-21
    Decision affects adjacent indication; potential read-through to ZENVARA.
  22. Payerlow (23%)health plan commercialtier changed
    2025-07-29
    Cigna moved ZENVARA from preferred to non-preferred tier.
    CignaUS-nationallives: 25,295,976effective: 2025-09-21
    Decision concerns ZENVARA's reference product.
    tier_before: 3tier_after: 4
  23. Payerlow (33%)pbm commercialadded
    2025-07-31
    Express Scripts added ZENVARA to NSCLC formulary tier 3 with PA.
    Express ScriptsUS-nationallives: 65,082,531effective: 2025-08-24
    Class-wide implications relevant to all assets with this mechanism.
  24. Payerlow (29%)icervalue assessment draft
    2025-08-04
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 56,921,292effective: 2025-08-04
    Decision affects adjacent indication; potential read-through to ZENVARA.
    rating: C-value_for_money: intermediateprice_benchmark_usd: 28106
  25. Payerlow (31%)cms lcdcoverage decision
    2025-08-08
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J5lives: 3,931,525effective: 2025-08-08
    Decision affects adjacent indication; potential read-through to ZENVARA.
  26. Payerlow (28%)pbm commercialadded
    2025-08-09
    CVS Caremark added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS CaremarkUS-nationallives: 80,513,617effective: 2025-09-02
    Decision concerns ZENVARA's reference product.
  27. Payerlow (30%)pbm medicare pdpremoved
    2025-08-11
    Humana Pharmacy Solutions removed ZENVARA from formulary effective 2025-09-27.
    Humana Pharmacy SolutionsUS-nationallives: 11,910,809effective: 2025-09-27
    Decision affects adjacent indication; potential read-through to ZENVARA.
  28. Payerlow (28%)health plan commercialrestriction added
    2025-08-11
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 20,452,530effective: 2025-09-30
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: PA
  29. Payerlow (25%)pbm commercialstep therapy imposed
    2025-08-15
    Express Scripts now requires step therapy through alternative before ZENVARA.
    Express ScriptsUS-nationallives: 78,388,248effective: 2025-08-31
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: PA
  30. Payerlow (23%)cms lcdcoverage decision
    2025-08-18
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J8lives: 3,450,700effective: 2025-08-18
    Decision affects adjacent indication; potential read-through to ZENVARA.
  31. Payerlow (33%)cms lcdcoverage decision
    2025-08-29
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JNlives: 11,579,134effective: 2025-08-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
  32. Payerlow (36%)hospital pt committeeadded
    2025-08-31
    Ascension added ZENVARA to NSCLC formulary tier 3 with PA.
    AscensionUS-nationallives: 923,211effective: 2025-10-08
    Class-wide implications relevant to all assets with this mechanism.
  33. Payerlow (29%)health plan commercialrestriction removed
    2025-08-31
    BCBS Federal Employee Program removed step-therapy requirement on ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 7,374,306effective: 2025-08-31
    Decision affects adjacent indication; potential read-through to ZENVARA.
  34. Payerlow (21%)hta intlcoverage decision
    2025-09-02
    G-BA (Germany) issued coverage decision for ZENVARA in NSCLC.
    G-BA (Germany)EU-DElives: 36,279,145effective: 2025-09-02
    Decision affects adjacent indication; potential read-through to ZENVARA.
  35. Payerlow (31%)pbm medicare pdpremoved
    2025-09-06
    Express Scripts Medicare removed ZENVARA from formulary effective 2025-09-26.
    Express Scripts MedicareUS-nationallives: 5,985,157effective: 2025-09-26
    Class-wide implications relevant to all assets with this mechanism.
  36. Payerlow (22%)health plan commercialrestriction removed
    2025-09-12
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 15,286,678effective: 2025-09-12
    Class-wide implications relevant to all assets with this mechanism.
  37. Payerlow (37%)pbm medicare pdpremoved
    2025-09-14
    Humana Pharmacy Solutions removed ZENVARA from formulary effective 2025-10-09.
    Humana Pharmacy SolutionsUS-nationallives: 10,370,520effective: 2025-10-09
    Decision concerns ZENVARA's reference product.
  38. Payerlow (27%)pbm commercialrestriction added
    2025-09-24
    OptumRx added prior-authorization requirement to ZENVARA.
    OptumRxUS-nationallives: 83,989,935effective: 2025-10-29
    Decision affects adjacent indication; potential read-through to ZENVARA.
    restrictions: LA,PA
  39. Payerlow (30%)pbm commercialtier changed
    2025-09-24
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 99,528,452effective: 2025-10-09
    Decision affects adjacent indication; potential read-through to ZENVARA.
    tier_before: 2tier_after: 5
  40. Payerlow (31%)pbm medicare pdprestriction added
    2025-09-26
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 11,077,382effective: 2025-10-19
    Decision concerns ZENVARA's reference product.
    restrictions: QL,PA
  41. Payerlow (21%)pbm commercialexcluded
    2025-10-02
    OptumRx excluded ZENVARA from 2026 formulary effective 2025-10-25.
    OptumRxUS-nationallives: 73,367,527effective: 2025-10-25
    Decision affects adjacent indication; potential read-through to ZENVARA.
  42. Payerlow (29%)state medicaid pdlremoved
    2025-10-03
    Texas HHSC removed ZENVARA from formulary effective 2025-10-22.
    Texas HHSCUS-state:ILlives: 4,558,258effective: 2025-10-22
    Decision concerns ZENVARA's reference product.
  43. Payerlow (26%)hta intlvalue assessment final
    2025-10-04
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)EU-FRlives: 22,829,771effective: 2025-10-04
    Decision affects adjacent indication; potential read-through to ZENVARA.
  44. Payerlow (25%)pbm commercialstep therapy imposed
    2025-10-06
    OptumRx now requires step therapy through alternative before ZENVARA.
    OptumRxUS-nationallives: 78,695,958effective: 2025-11-26
    Class-wide implications relevant to all assets with this mechanism.
    restrictions: QL
  45. Payerlow (23%)pbm commercialadded
    2025-10-09
    CVS Caremark added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS CaremarkUS-nationallives: 80,386,033effective: 2025-10-23
    Class-wide implications relevant to all assets with this mechanism.